The company entered into talks with a distributor in Brazil following the regulatory approval.
LifeWave Hi-Tech Medical Devices Ltd. (TASE:LIFE) has obtained marketing approval for its BST (bioelectrical signal therapy) for the treatment of chronic sores from Brazil's National Health Surveillance Agency (ANVISA).
LifeWave's share price jumped over 10% on the news, but quickly fell back. By late morning, the share price was up 4% to NIS 2.45, giving a market cap of NIS 35 million.
LifeWave already obtained international UL safety standard certification for BST. Following ANVISA's approval, the company said that it has begun negotiations with a Brazilian distributor for a distribution contact for BSL in the country.
Published by Globes [online], Israel business news - www.globes-online.com - on August 10, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010